Breaking News
August 17, 2018 - Team explores diabetes drug’s ability to treat RSV infection
August 17, 2018 - New imaging technique can spot tuberculosis infection in an hour | News Center
August 17, 2018 - PolyU researchers design new self-fitting scaffold to induce bone regeneration
August 17, 2018 - CartiHeal and LSU Health successfully enroll first two patients in Agili-C IDE pivotal study
August 17, 2018 - Less-invasive options are slowing disease progression in glaucoma patients
August 17, 2018 - Researchers discover new promising target point for cancer and diabetes therapies
August 17, 2018 - Podcast: KHN’s ‘What the Health?’ See you in court!
August 17, 2018 - New mobile phone application enables early detection of cerebral ictus
August 17, 2018 - UK’s leading sight loss charity invites applications from brightest minds in ophthalmic research
August 17, 2018 - Researchers produce artificial placenta model that closely resembles natural organ
August 17, 2018 - FDA Alert: Temporary Total Artificial Heart Companion 2 Driver System by SynCardia Systems: Letter to Health Care Providers
August 17, 2018 - Researchers discover why sepsis from a staph infection causes organ failure
August 17, 2018 - Revealed: The molecular mechanism underlying hypertrophic cardiomyopathy | News Center
August 17, 2018 - Research explores relationship between personal history of infectious fever and cancer risk
August 17, 2018 - Study finds rise in cases of progressive massive fibrosis among U.S. coal miners
August 17, 2018 - NEDBELS project examines impact of neurodiversity concept on legal systems
August 17, 2018 - Seeking solutions to treat scleroderma
August 17, 2018 - Statins may improve conditions of people with rare lung disease
August 17, 2018 - Study finds why some people with brain markers of Alzheimer’s never develop dementia
August 17, 2018 - Life Biosciences contributes $100,000 to fund its biomedical innovation course on aging
August 17, 2018 - Researchers develop a set of health outcome measures for children with complex medical situations
August 17, 2018 - Many Americans Not Being Assessed for Depression
August 17, 2018 - Scientists report setbacks in quest for AIDS cure
August 17, 2018 - Christopher Gardner busts myths about milk | News Center
August 17, 2018 - Bacterial activity in child’s mouth may serve as biomarkers for autism spectrum disorder
August 17, 2018 - Scripps Research scientists uncover new approach for treating thrombocytopenia
August 17, 2018 - Mathematical model shows the influence of human behavior on spread of infectious diseases
August 17, 2018 - Valley Hospital achieves Magnet recognition for fourth consecutive time
August 17, 2018 - Researchers describe link between poor oocyte development and oxidative stress in obese mice
August 17, 2018 - Hospitals battle for control over fast-growing heart-valve procedure
August 17, 2018 - AHA: Home-Delivered Meals Keep Heart Failure Patients Out of Hospital
August 17, 2018 - In Southern Mozambique, only half of people diagnosed with HIV enroll in medical care
August 17, 2018 - Researchers discuss techniques to help combat growing epidemic of obesity
August 17, 2018 - Researchers develop novel statistical method to evaluate gene-to-gene interactions linked with cancer
August 17, 2018 - Island Fertility joins Stony Brook Community Medical to provide comprehensive fertility care
August 17, 2018 - Study shows link between thinning of the retina and early sign of Parkinson’s disease
August 17, 2018 - Digital birth control app gets FDA nod
August 17, 2018 - FDA grants approval for first generic version of epinephrine auto-injector
August 17, 2018 - Federal advisory group publishes recommendations on prevention of acute, chronic pain
August 17, 2018 - 3D-printed human body parts to be used as teaching aids for surgical training
August 17, 2018 - U.S. murder, suicide rates climbing again
August 17, 2018 - This is your brain on… roller coasters?
August 17, 2018 - Report discusses whether all newborns should undergo genetic sequencing
August 17, 2018 - UCR receives 2018 Inspiring Programs in STEM Award from INSIGHT Into Diversity magazine
August 17, 2018 - Researchers publish new paper on developing vaccine candidates for Helminthic parasites
August 17, 2018 - Researchers develop new method to diagnose broad range of cancers using malaria protein
August 17, 2018 - Female mosquitoes quickly evolve selective mating behavior when faced with threats
August 17, 2018 - FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
August 17, 2018 - Resistance training and exercise motivation go hand-in-hand
August 17, 2018 - A lesson for future doctors: Listen to and learn from your patients
August 17, 2018 - NUS study discovers a bidirectional regulator and shines light on A-to-I RNA editing in cancer cells
August 17, 2018 - Research shows link between high blood levels of omega-3s and better brain function in children
August 17, 2018 - Researchers propose new theory for how rare gene mutations cause Alzheimer’s disease
August 17, 2018 - New project to combat DMD-related fibrosis receives major funding boost
August 17, 2018 - Digital psychiatric therapy can ‘rewire’ the brain in children with ADHD, study shows
August 17, 2018 - Psychologist to assess how the brain maintains precise short-term and long-term memories
August 17, 2018 - Eating white button mushrooms could improve regulation of glucose in the liver
August 17, 2018 - Scientists identify mutational signatures in ovarian cancer
August 17, 2018 - Sun Pharma receives U.S. FDA approval for CEQUA to treat patients with dry eye disease
August 17, 2018 - Teva Announces Updated Indication and Vial Presentation for Granix (tbo-filgrastim) Injection in United States
August 17, 2018 - Study shows DNA methylation related to liver disease among obese patients
August 17, 2018 - Life on the border: Back at Stanford, ready to pitch in
August 17, 2018 - New device for accurately placing hemodialysis catheters on kidney patients
August 17, 2018 - New strategy accelerates, automates process of prototype molecule optimization
August 17, 2018 - Study finds role of autoimmunity in development of COPD
August 17, 2018 - Researchers transform research tool to study neuronal function
August 17, 2018 - Cognitive impairment does not equate to unhappiness in older adults
August 17, 2018 - Peer Comparisons Can Decrease Risky Prescribing Patterns
August 17, 2018 - Susceptible genes identified for childhood chronic kidney disease
August 17, 2018 - Research uncovers miscarriage cause, identifies potential targets for treatment
August 17, 2018 - Bacterial armor could be new target for antibiotics | News Center
August 17, 2018 - FDA expands approval of Vertex’ cystic fibrosis medicine to treat children aged 12 to
August 17, 2018 - Give Your Child a Head Start With Math
August 17, 2018 - Ground-breaking study tests whether rejected livers can be made viable for transplantation
August 16, 2018 - New algorithm could improve diagnosis of rare diseases | News Center
August 16, 2018 - SCHILLER introduces latest generation of ECG device, CARDIOVIT AT-102 G2
August 16, 2018 - Proper treatment, refraining from smoking can reduce heart disease risk from type 2 diabetes
August 16, 2018 - Mount Sinai study could transform treatment for patients with retinal degenerative diseases
August 16, 2018 - Penn researchers develop first mouse model of idiopathic pulmonary fibrosis
August 16, 2018 - Four tips to help prevent fall allergy symptoms
Antibodies against hemorrhagic fever disarm two viruses of same family

Antibodies against hemorrhagic fever disarm two viruses of same family

image_pdfDownload PDFimage_print

Hemorrhagic fever viruses, so named for their ability to induce massive, and at times fatal, internal bleeding, captured the world’s attention during the Ebola outbreak of 2014-2016 in West Africa.

But these pathogens’ high lethality, fickle seasonal and geographic patterns, compounded by a lack of preventive therapies, have frustrated scientific and public health efforts to avert outbreaks for far longer than the recent epidemics.

The ultimate quest of those efforts is to develop a universal vaccine that works against multiple viruses and to design other broad-spectrum antibody therapies to rapidly treat those already infected.

Now, in a small but illuminating study, Harvard Medical School scientists report that antibodies made in response to a vaccine against one hemorrhagic fever virus–Junin–can successfully disarm one of its cousins, Machupo, for which there’s currently no vaccine. The experiments were conducted in vitro using antibodies obtained from a vaccine recipient.

Although limited to two viruses from one family, the results set the stage for the design of broad-spectrum therapies that can work against multiple or all members of a viral family, despite significant differences in molecular makeup, the researchers say.

The findings, published May 14 in Nature Communications, build on isolated reports that people and primates vaccinated against Junin appear to be more resilient to Machupo. The new study, however, provides the first molecular proof of what thus far have been merely anecdotal observations. It also identifies a common, conserved site on both viruses that renders them defenseless to the same antibodies.

“Our findings raise the tantalizing possibility of designing universal therapies using antibodies made to one virus for which there is a vaccine as a way to prevent or treat other viruses for which there are none,” said study senior author Jonathan Abraham, assistant professor of microbiology and immunobiology at Harvard Medical School and an infectious disease specialist at Brigham and Women’s Hospital. “We believe our results are a step in that direction.”

The need to develop such therapies, the team said, is even more acute in an era when viruses previously limited to one region are appearing in new geographic areas, greatly fueling the risk for outbreaks in new settings.

Junin and Machupo belong to the Arenaviridae family, composed of more than 30 viruses. Of those, five are known to cause human disease in South America.

Even though viruses from other viral families can at times cause hemorrhagic fevers, members of the arenavirus family are considered true hemorrhagic fever viruses. The infections they cause are marked by blood vessel damage and severe bleeding in multiple organs. Between 15 and 30 percent of people infected with one these viruses develop severe symptoms and die.

Prior to the development of the Junin vaccine in the 1980s, the virus had caused about 30,000 symptomatic infections in Argentina. The vaccine, which contains a weakened form of the virus, induces immunity and lifelong protection in about 95 percent of people who get it. As a result, the incidence of Argentine hemorrhagic fever declined dramatically from 2,000 to 50 to 60 cases a year.

By comparison, outbreaks caused by Machupo have been relatively small and contained–fewer than 100 people sick at a time. Then again, Abraham points out, up until the 2014-2016 outbreaks in West Africa, Ebola too had caused sporadic, smaller outbreaks affecting dozens to hundreds of people.

“We can’t reliably forecast future viral behavior based on past ones,” Abraham said. “This is why preemptively developing treatment and prevention strategies is so crucial.”

Since the 1980s, scientists have tried to replicate the success of the Junin vaccine by developing a vaccine that acts against multiple or all viruses of the same family.

Traditionally, scientists have homed in on one promising commonality across related viruses: they tend to use the same gateway into their hosts–be they animals or people–a sort of “molecular key,” called a protein receptor binding site (RBS), which fits into surface proteins on the host cell like a key in a lock. The RBS tends to be well-conserved across members of the same viral family because evolution discourages frequent mutations to a structure so critical for an organism’s survival.

Over the last decade, researchers have worked to develop antibody treatments that mimic the “lock” of the host cells as a way to fool the virus into thinking it’s attached to a host cell, when in fact, it’s locked into an antibody that renders it incapable of entering and infecting host cells. But, as is often the case in the evolutionary plot, there’s a twist, Abraham explains.

As a virus’ natural host, or target, evolves over time, so do the footprints, or the configuration, of the its molecular key–the RBS. The change ensures the virus’ compatibility with the host and, in the end, the virus’ survival. Viruses limited to certain geographic regions and the hosts specific to those regions shapeshift along with their targets. Thus, members of the same viral family residing in different geographic areas and exposed to different hosts will have both commonalities and differences in their RBS.

“Even among viruses that are related and share similarities in the molecular makeup of their receptor bindings sites, you still end up with a substantial degree of variability,” Abraham said.

This variability, researchers say, has foiled efforts to design broad-acting protective antibodies toward one hemorrhagic fever virus as a way to disarm others.

In the new study, however, researchers identified a tiny portion in the molecular keys used by Junin and Machupo that is identical and responds to the same antibodies, rendering both viruses sensitive to the same vaccine.

For their experiments, the team started out by obtaining antibodies from a person who had received the Junin vaccine two years prior. They focused on a subset of immune cells known as memory B cells. As the long-term keepers of memories from viral encounters past, these cells store the ingredients and the recipes for making protective antibodies against these remembered viruses. When these cells encounter the same virus later, they quickly dust off the recipe and crank up the production of antibodies to disarm the virus.

It is from these very cells that the scientists isolated several Junin-specific antibodies developed as a result of past vaccination. Next, they tested in a lab dish these antibodies’ affinity for binding to the RBS of the Machupo virus. Two of the handful of antibodies ended up binding to it.

The researchers used X-ray crystallography to pinpoint the exact location and other molecular details of the interaction between the viral RBS and the two antibodies. The visualization technique identified the precise location where virus and antibody latched onto one another–a genetically identical section shared by both Machupo and Junin. That, researchers said, is the very molecular chink that renders both viruses vulnerable to the same vaccine antibodies.

This conserved part of the viruses’ molecular keys is a promising target for developing antibody therapies against multiple hemorrhagic fever viruses.

Junin and Machupo are the most closely related viruses of the Arenavirus family. Even so, more than half of their RBS molecular makeup is different. The new findings, however, suggest that such common areas of vulnerability may exist among other members of the Arenavirus family.

“This approach can play an important role in controlling human infection and its most devastating consequences–a goal that’s remained elusive,” Abraham said. “As we get better in our ability to home in on progressively tinier parts shared across all viruses, we can start eyeing new precision-targeted therapies designed to work on conserved areas across multiple viral species.”

Source:

https://hms.harvard.edu/news/silver-bullet

Tagged with:

About author

Related Articles